Pediatric Respiratory Hospitalizations in the Pre-COVID-19 Era: The Contribution of Viral Pathogens and Comorbidities to Clinical Outcomes, Valencia, Spain

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Castells, Valerie Bosch
  • Mira-Iglesias, Ainara
  • Lopez-Labrador, Francisco Xavier
  • Mengual-Chulia, Beatriz
  • Carballido-Fernandez, Mario
  • Mollar-Maseres, Joan
  • Puig-Barbera, Joan
  • Diez-Domingo, Javier
  • Chaves, Sandra S.

Grups d'Investigació

Abstract

Viral respiratory diseases place a heavy burden on the healthcare system, with children making up a significant portion of related hospitalizations. While comorbidities increase the risk of complications and poor outcomes, many hospitalized children lack clear risk factors. As new vaccines for respiratory viral diseases emerge, this study examined pediatric respiratory hospitalizations, focusing on viral etiology, complication rates, and the impact of comorbidities to guide future policy. Data were analyzed from eight pre-COVID influenza seasons (2011/2012-2018/2019) involving patients under 18 years hospitalized with respiratory complaints across 4-10 hospitals in Valencia, Spain. Respiratory specimens were tested for eight viral targets using multiplex real-time reverse-transcription polymerase chain reaction. Demographics, clinical outcomes, discharge diagnoses, and laboratory results were examined. Among the hospitalized children, 26% had at least one comorbidity. These children had higher rates of pneumonia, asthma exacerbation, and pneumothorax, and were twice as likely to require ICU admission, though mechanical ventilation and length of stay were similar to those without comorbidities. Respiratory syncytial virus (RSV) was the most common virus detected (23.1%), followed by rhinovirus/enterovirus (9.5%) and influenza (7.2%). Viral codetection decreased with age, occurring in 4.6% of cases. Comorbidities increase the risk of complications in pediatric respiratory illnesses, however, healthcare utilization is driven largely by otherwise healthy children. Pediatric viral vaccines could reduce this burden and should be further evaluated.

Dades de la publicació

ISSN/ISSNe:
1999-4915, 1999-4915

VIRUSES-BASEL  MDPI

Tipus:
Article
Pàgines:
-
PubMed:
39459854
Factor d'Impacte:
1,463 SCImago
Quartil:
Q1 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Keywords

  • respiratory viruses; hospitalizations; children; comorbidities; complications; severity; viral codetection

Projectes associats

Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

LET-INM-2020 . 2023

Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

MM09-SIT-023 . 2023

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA).

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

D3250C00024 . 2023

Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

2023

Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dupilumab en niños de 2 a <6 años con asma no controlada y/o sibilancias asmáticas graves recurrentes.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

EFC14771 . 2024

Estudio fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON).

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

D5180C00016 . 2024

Estudio epidemiológico de las enfermedades alérgicas pediátricas en España.

Investigador Principal: MIGUEL TORTAJADA GIRBÉS

ALERGOPEDIÁTRICA 2020 . 2024

Compartir la publicació